4D Molecular Therapeutics Inc

NASDAQ:FDMT   9:51:08 AM EDT
3.73
+0.02 (+0.54%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)172.79M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.39 Million
Adjusted EPS-$0.73
See more estimates
10-Day MA$3.94
50-Day MA$3.70
200-Day MA$6.01
See more pivots

4D Molecular Therapeutics Inc Stock, NASDAQ:FDMT

5858 Horton Street, Suite 455, Emeryville, California 94608
United States of America
Phone: +1.510.505.2680
Number of Employees: 227

Description

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.